Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2022-01-05 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2021. It details movements in issued shares, share options, and other share-related information for Simcere Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, management discussion, or earnings data. It is a regulatory filing related to share capital movements and compliance with listing rules, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS).
2022-01-05 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM0270 ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the clinical trial approval for a drug (SIM0270) issued by the National Medical Products Administration. It is a short announcement (2945 characters) informing shareholders and investors about a business development related to clinical trial approval. There are no financial statements, no detailed financial data, no regulatory certifications, or voting results. The document is not a full report but an announcement of a specific event related to the company's operations. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-12-28 English
CONTINUING CONNECTED TRANSACTIONS
Regulatory Filings Classification · 95% confidence The document is an announcement by Simcere Pharmaceutical Group Limited regarding entering into continuing connected transactions involving property leases and service agreements with related parties. It references compliance with the Hong Kong Stock Exchange Listing Rules, specifically Chapter 14A concerning connected transactions. The document details the terms, pricing policies, historical transaction amounts, and proposed annual caps for these transactions. It is structured as a formal announcement to shareholders and the market about these continuing connected transactions, including disclosures about related parties and compliance with regulatory requirements. There is no indication that this is a full financial report, audit report, earnings release, or management discussion. It is not a proxy solicitation, voting result, or AGM material. The content fits the category of a regulatory announcement about connected transactions under stock exchange rules, which is best classified as a Regulatory Filing (RNS). The document length (15,000 characters) and detailed content support that it is a substantive announcement rather than a brief notice or report publication announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-12-23 English
GRANT OF AWARDS AND ISSUE OF NEW SHARES UNDER THE 2021 RSU SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the grant of awards and the issue of new shares under the 2021 RSU (Restricted Share Unit) Scheme. It details the number of RSUs granted, the vesting dates, trustees involved, and the application for listing of the underlying shares. The content focuses on share issuance related to employee incentive schemes and capital structure changes. There is no financial performance data, earnings information, or management discussion of results. The document is not a full financial report but an announcement about share issuance and awards under a share scheme. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues or capital changes. The document length is sufficient and contains substantive information about the share issuance event itself, not just a brief notice or report publication announcement.
2021-12-23 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE INCLUSION OF TRILACICLIB FOR INJECTION AS A PRIORITY REVIEW DRUG BY CDE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the inclusion of their drug Trilaciclib for injection as a priority review drug by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. It provides business development information about the drug, its collaboration with G1 Therapeutics, and background about the company. The document is relatively short (3560 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is an announcement of a business development event rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2021-12-22 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO STRATEGIC COOPERATION WITH AVILEX TO INTRODUCE INNOVATIVE DIMERIC PSD-95 INHIBITOR
Capital/Financing Update Classification · 90% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding a strategic cooperation agreement with Avilex Pharma ApS to develop and commercialize a drug candidate. It is an announcement of a business development event, specifically a strategic cooperation, rather than a financial report, regulatory filing, or management change. The document does not contain financial data, voting results, or details of board changes. It is not a call transcript, earnings release, or capital update. The content focuses on a strategic partnership and business development, which aligns with Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, or possibly a Regulatory Filing (RNS) if it does not fit elsewhere. However, since it is a voluntary announcement about a strategic cooperation agreement that could impact the company's business and potentially its capital or financing prospects, CAP is the most appropriate classification. The document length is under 5,000 characters and is an announcement, but it is not about report publication or certification, so RPA or RNS are less fitting. Therefore, the best classification is CAP with high confidence.
2021-12-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.